Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,012,798
  • Shares Outstanding, K 127,274
  • Annual Sales, $ 829,250 K
  • Annual Income, $ 281,590 K
  • 60-Month Beta 1.27
  • Price/Sales 8.07
  • Price/Cash Flow 16.74
  • Price/Book 38.00
Trade HALO with:

Options Overview Details

View History
  • Implied Volatility 36.50% ( -4.43%)
  • Historical Volatility 40.05%
  • IV Percentile 26%
  • IV Rank 42.97%
  • IV High 58.43% on 10/27/23
  • IV Low 19.97% on 06/04/24
  • Put/Call Vol Ratio 0.18
  • Today's Volume 401
  • Volume Avg (30-Day) 249
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 7,263
  • Open Int (30-Day) 6,679

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.73
  • Number of Estimates 5
  • High Estimate 0.81
  • Low Estimate 0.68
  • Prior Year 0.68
  • Growth Rate Est. (year over year) +7.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.99 +12.26%
on 06/18/24
55.29 -0.52%
on 07/16/24
+5.34 (+10.75%)
since 06/17/24
3-Month
37.73 +45.77%
on 04/19/24
55.29 -0.52%
on 07/16/24
+16.98 (+44.66%)
since 04/17/24
52-Week
32.83 +67.53%
on 10/25/23
55.29 -0.52%
on 07/16/24
+14.73 (+36.58%)
since 07/17/23

Most Recent Stories

More News
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/CNW/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding...

ONCY : 1.0900 (+1.87%)
CADL : 7.30 (+0.14%)
AZN : 78.59 (-0.15%)
HALO : 55.00 (-0.18%)
JANX : 45.29 (-2.35%)
ONC.TO : 1.48 (-0.67%)
Rising Cancer Rates Drive Biotech Advancements Despite Political Hurdles

USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden’s “Cancer...

ONCY : 1.0900 (+1.87%)
ONC.TO : 1.48 (-0.67%)
CADL : 7.30 (+0.14%)
AZN : 78.59 (-0.15%)
HALO : 55.00 (-0.18%)
JANX : 45.29 (-2.35%)
Halozyme Therapeutics: Q1 Earnings Snapshot

Halozyme Therapeutics: Q1 Earnings Snapshot

HALO : 55.00 (-0.18%)
Halozyme Therapeutics: Q4 Earnings Snapshot

Halozyme Therapeutics: Q4 Earnings Snapshot

HALO : 55.00 (-0.18%)
Plexus, SunPower fall; Progress Software, Masonite International rise, Wednesday, 1/17/2024

Stocks that traded heavily or had substantial price changes on Wednesday: Plexus, SunPower fall; Progress Software, Masonite International rise

PLXS : 118.90 (+5.42%)
SPWR : 2.62 (-2.60%)
BGFV : 2.75 (-3.22%)
PRGS : 56.53 (+2.56%)
HALO : 55.00 (-0.18%)
PI : 175.00 (-2.68%)
DOOR : 132.84 (+0.05%)
4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond

Healthcare stocks have underperformed in 2023, but that is expected to change this year.

CNC : 67.00 (-3.05%)
HALO : 55.00 (-0.18%)
ABCL : 3.45 (-1.15%)
HUM : 394.05 (-0.39%)
Halozyme Therapeutics: Q3 Earnings Snapshot

Halozyme Therapeutics: Q3 Earnings Snapshot

HALO : 55.00 (-0.18%)
Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb (BMS) reported positive topline results from...

HALO : 55.00 (-0.18%)
Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") will present the positive results of a clinical study demonstrating subcutaneous...

HALO : 55.00 (-0.18%)
Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the approval of Roche's Tecentriq® SC (atezolizumab), using Halozyme's...

HALO : 55.00 (-0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company...

See More

Key Turning Points

3rd Resistance Point 58.82
2nd Resistance Point 57.05
1st Resistance Point 56.08
Last Price 55.00
1st Support Level 53.34
2nd Support Level 51.57
3rd Support Level 50.60

See More

52-Week High 55.29
Last Price 55.00
Fibonacci 61.8% 46.71
Fibonacci 50% 44.06
Fibonacci 38.2% 41.41
52-Week Low 32.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar